Nexalin Technology, Inc. (NXL) announced progress in its U.S. regulatory pathway for Alzheimer's disease following a series of high-level meetings with the U.S. Food and Drug Administration (FDA) and international experts.
The company is developing its non-invasive Deep intracranial Frequency Stimulation (DIFS) technology as a drug-free approach to reduce Alzheimer's symptoms and cognitive decline. During a recent FDA Q-Submission meeting, regulators provided guidance on clinical trial design, including primary and secondary endpoints to measure treatment response in Alzheimer's patients. Nexalin plans to submit an amended application in the second quarter of 2026.
The strategy builds on extensive real-world neurostimulation data from both U.S. and China, where Nexalin collaborates with leading Alzheimer's specialists, including Professor Yi Tang, M.D., PhD, Vice Chairman of Xuanwu Hospital at Capital Medical University. The company emphasized that aligning global experience with FDA requirements is a critical step toward advancing its De Novo application and positioning DIFS as a novel therapy for age-related cognitive vulnerability.
"These meetings marked a critical step in aligning our global clinical experience with a disciplined U.S. regulatory and clinical strategy," said Mark White, President and CEO of Nexalin Technology. He noted that the upcoming FDA trial design will directly reflect insights from these discussions.
NXL has traded between $0.33 and $2.00 over the past year. The stock is currently trading at $0.47, up 11.66%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.